Lifespan Health and Aging
Featured Topics
Lead story
Other featured articles
-
Conflicts of Interest in Dialysis: A Barrier to Policy Reforms
What are the possible benefits and risks of nephrologist’s financial participation in dialysis facility joint venture (JV) arrangements and financial participation in End‐stage Kidney Disease Seamless Care Organizations (ESCOs)? Eugene Lin and co-authors examine possible mechanisms for disclosure and reporting of such arrangements as well as risk mitigation.
Posted in -
Four Years Into MACRA: What Has Changed?
Changes to nephrology reimbursement present a unique opportunity to improve patient outcomes in a cost‐effective way. A multidisciplinary effort among policy makers, nephrology providers, and patient advocacy groups is critical to ensure these changes in care delivery safeguard and improve patient health.
Posted in -
Policy Issues in Dialysis Care
The challenges that policymakers face when trying to encourage the delivery of high quality, cost‐efficient dialysis care to all patients who require dialysis are evident in the state of dialysis care today.
Posted in -
The Potential Emergence of Disease-Modifying Treatments for Alzheimer Disease: The Role of Primary Care in Managing the Patient Journey
Research by Jakub Hlavka and colleagues suggests a combination of brief cognitive tests and blood-based biomarker tests will allow primary care physicians to identify patients with potential early stage Alzheimer’s disease efficiently and triage them for further evaluation.
Posted in
About this section
People are living longer, which brings obvious benefits as well as considerable challenges — from Alzheimer’s and other age-related diseases to increased injuries, disabilities and poverty risks. Policymakers around the world rely on Schaeffer Center research and modeling tools for finding ways to help keep people as healthy as possible throughout their lives.
Our Experts On Lifespan Health and Aging
Our Work In Lifespan Health and Aging
-
Future Health Dividends for California: Valuing Medical Innovations
Reducing the incidence of four common cancers (breast, colon, lung, and prostate cancer), diabetes and stroke by 50 percent would generate nearly $900 billion in social value for California between 2018 and 2040. Just a 10 percent decline generates $175 billion over the same period.
Categorized in -
Does Medicare Coverage Improve Cancer Detection and Mortality Outcomes?
This study provides the first evidence to our knowledge that near-universal access to Medicare at age 65 is associated with improvements in population-level cancer mortality, and provides new evidence on the differences in the impact of health insurance by gender.
-
Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017
High and rising launch prices of new cancer drugs have raised American public stakeholder and policy concern. A key policy question is whether the clinical gains offered by these drugs in treating specific cancer indications justify the price increases.
Categorized in -
Measuring Alzheimer’s Disease and Other Dementias in Diverse Populations Using Medicare Claims Data
The researchers examined how methods used for identifying dementia in administrative claims affected dementia incidence across racial/ethnic populations using a 100% sample of Medicare beneficiaries.
-
Longitudinal Analysis of Dementia Diagnosis and Specialty Care Among Racially Diverse Medicare Beneficiaries
The burden of Alzheimer’s disease and other dementias is rapidly growing. Researchers found vast majority of dementia patients don’t receive specialty diagnosis and care.
-
Assessing the Preparedness of the Canadian Health Care System Infrastructure for an Alzheimer’s Treatment
A report on Canadian readiness to deal with new Alzheimer’s disease treatments co-authored by Jakub Hlávka found that average wait times could reach 28 months and that the most pressing issue is a lack of dementia specialists.
Categorized in